No Data
No Data
Earnings Preview: YMAB to Report Financial Results Pre-market on May 13
$Y-mAbs Therapeutics(YMAB.US)$ is scheduled to release its financial results pre-market on May 13 ET. Earnings PreviewAnalysts estimate $Y-mAbs Therapeutics(YMAB.US)$ to post revenue of USD19.61M
Rhythm Pharmaceuticals Y-mAbs' Cancer Drug DANYELZA Wins Key NCCN Recommendation for High-Risk Neuroblastoma
Express News | Y-mAbs Announces Update to National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-Gqgk (Danyelza®)
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Y-mAbs Therapeutics | 10-K/A: Annual report (Amendment)
BofA Securities Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $3